ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1966

Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged?

Federico Fattorini1, Chiara Cardelli1, Simone Barsotti2, Michele Diomedi1, Elenia Laurino1, Mariano Grosso3, Linda Carli1 and Marta Mosca1, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2Internal Medicine, Ospedale di Livorno, Pisa, Italy, 3Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy

Meeting: ACR Convergence 2023

Keywords: Comorbidity, Myopathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-synthetase syndrome (ASS) is an idiopathic inflammatory myopathy, typically characterized from the triad interstitial lung disease (ILD), myositis and arthritis, together with anti-aminoacyl tRNA synthetase (ARS) antibodies (Ab) positivity. Recent data suggested esophageal involvement could commonly occurs, being related to a higher risk of pulmonary complications, at first ab ingestis pneumonia, able to significantly worsen the respiratory function of ASS patients and related to a poor prognosis. Esophageal involvement can be assessed using both double-contrast conventional radiology (DCCR) and oro-pharyngeal-esophageal scintigraphy (OPES). Moreover, DCCR may show the presence of gastrointestinal (GI) pathologies, such as esophagitis, achalasia and hiatal hernia, with a prevalence in Italian population up to 33%, 0.03% and 10% respectively. The first aim of the study is to evaluate the prevalence of esophageal involvement in a monocentric cohort of patients with ASS; secondly, we aimed at comparing DCCR and OPES in highlighting swallowing dysfunctions or GI comorbidities.

Methods: We retrospectively analyzed medical records of consecutive patients with a diagnosis of ASS based on both physicians’ clinical diagnosis and ARS Ab positivity, regularly followed at our Myositis Clinic from January 2018 to May 2023. Demographic and clinical data of patients, together with DCCR and OPES results were collected; moreover, patients were asked to fill in MD Anderson Dysphagia Inventory (MDADI) to evaluate their dysphagia. Intergroups comparisons were assessed by using Chi-square, t-test and ANOVA. P values < 0.05 were considered significant.

Results: We included 37 patients (21 female, 56.8%) with a mean age of 56.3±7.9 years; 12 (32.5%) reported dysphagia and, on 31 (83.7%) who filled in MDADI, 9 (29%) showed scores corresponding to a swallowing disability, significantly associated to subjective dysphagia (p< 0.001). Twenty patients (54.1%) performed OPES; up to 5/20 (25%) showed an increased esophageal (E) transit time (TT), oropharyngeal (OP) retention index (RI) was increased in up to 17/20 patients (85%) and E RI was increased in up to 12/20 patients (60%). DCCR was performed in 14 patients (37.8%); hypotone and hypokinesis were found in 7/14 (50%); besides, DCCR highlighted the presence of achalasia, esophagitis and hiatal hernia respectively in 7 (50%), 10 and 10 (71.4%) patients.

Conclusion: Less than one third of ASS patients perceive to have dysphagia; however, up to 85% of those who underwent OPES and up to 50% of those who performed DCCR showed a significant swallowing dysfunction. Moreover, DCCR showed a significantly higher prevalence of GI comorbidities in ASS patients than in the general population. This is the first study at our knowledge analyzing the prevalence of esophageal involvement in ASS, through 2 different methods and in comparison with patients’ perception of dysphagia. Further studies are needed to confirm our data, but they already could suggest to investigate GI involvement and GI comorbidities in ASS, even in asymptomatic patients, with the aim of optimizing their quality of care, also reducing the risk of respiratory complications related to dysphagia.


Disclosures: F. Fattorini: None; C. Cardelli: None; S. Barsotti: None; M. Diomedi: None; E. Laurino: None; M. Grosso: None; L. Carli: None; M. Mosca: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Otsuka, 2, UCB, 2.

To cite this abstract in AMA style:

Fattorini F, Cardelli C, Barsotti S, Diomedi M, Laurino E, Grosso M, Carli L, Mosca M. Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged? [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/investigating-esophageal-involvement-in-anti-synthetase-syndrome-how-to-discover-the-submerged/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigating-esophageal-involvement-in-anti-synthetase-syndrome-how-to-discover-the-submerged/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology